XML 60 R37.htm IDEA: XBRL DOCUMENT v3.25.0.1
Development and Other Agreements (Details) - USD ($)
$ / shares in Units, $ in Millions
 3 Months Ended 12 Months Ended
Mar. 31, 2024
Dec. 31, 2023
Mar. 31, 2022
Dec. 31, 2021
Dec. 31, 2018
Dec. 31, 2019
Dec. 31, 2024
Dec. 31, 2022
Dec. 28, 2018
Development Agreements [Line Items]                  
Shares Issued In Connection With The Restated Collaboration Agreement     2,900,000            
Gross Carrying Amount   $ 195.5         $ 193.5    
Potential common stock issued shares (in shares) 1,500,000                
Verily Life Sciences | Collaborative Arrangement                  
Development Agreements [Line Items]                  
Amortization period (in months)               64 months  
Collaborative Arrangement, Initial Payment | Verily Life Sciences | Collaborative Arrangement                  
Development Agreements [Line Items]                  
Closing stock price (in usd per share)                 $ 29.57
Initial payment on collaborative agreement         $ 250.0        
Issuance of common stock in connection with acquisition, shares (in shares)         7,400,000        
Collaborative research and development fee       $ 87.1 $ 217.7        
Collaborative Arrangement, Milestone Payments | Verily Life Sciences | Collaborative Arrangement                  
Development Agreements [Line Items]                  
Collaborative research and development fee           $ 3.2      
Gross Carrying Amount               $ 152.4  
Potential future common stock issuable (in shares)                 5,200,000
Potential common stock issued shares (in shares)   3,700,000